mTOR inhibitors in the treatment of cancer

Expert Opinion on Investigational Drugs

Volumn 17, Issue 11, 2008, Pages 1717-1734

  Fasolo, Angelica ^a   Sessa, Cristiana ^a,b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

Deforolimus; Everolimus; Mammalian target of rapamycin; Sirolimus; Temsirolimus

Indexed keywords

ALPHA INTERFERON; AP 23573; BEVACIZUMAB; BEZ 235; CYCLIN D; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; EXELIXIS; INSULIN RECEPTOR SUBSTRATE 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PROTEIN KINASE B; PROTEIN P53; RAPAMYCIN; RAPAMYCIN DERIVATIVE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; XL 147; XL 765;

ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BIPOLAR DISORDER; BLEEDING DISORDER; BLOOD TOXICITY; BONE MARROW DISEASE; CANCER INHIBITION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; DYSPNEA; EPISTAXIS; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MACULOPAPULAR RASH; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; METABOLIC DISORDER; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHUMAN; PERIPHERAL EDEMA; PNEUMONIA; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN TOXICITY; SOLID TUMOR; STOMATITIS; STRUCTURE ANALYSIS; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 54949144410     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.11.1717     Document Type: Review

References (105)

1. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot 1975;28:727-32
2. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot 1975;28:721-6
3. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998;31:335-40
4. Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991;251:283-7
5. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int 2001;59:3-16
6. Dancey JE. MTOR and related pathways. Cancer Biol Ther 2006;5:1065-73
7. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994;369:756-8
8. Chiu MI, Katz H, Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci USA 1994;91:12574-8
9. Sabatini DM, Erdjument-Bromage H, Lui M, et al. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994;78:35-43
10. Kunz J, Henriquez R, Schneider U, et al. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 1993;73:585-96
11. Helliwell SB, Wagner P, Kunz J, et al. TOR1 and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast. Mol Biol Cell 1994;5:105-18
12. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-88
13. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor - mTOR complex. Science 2005;307:1098-101
14. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptorindependent pathway that regulates the cytoskeleton. Curr Biol 2004;14:1296-302
15. Jacinto E, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004;6:1122-8
16. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-34
17. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45.
18. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48
19. Miron M, Lasko P, Sonenberg N. Signalling from Akt to FRAP/TOR targets both 4E-BP and S6K in Drosophila melanogaster. Mol Cell Biol 2003;23:9117-26
20. Tee AR, Manning BD, Roux PP, et al. Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signalling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003;13:1259-68
21. Chen J, Zheng XF, Brown EJ, Schreiber SL. Identification of an 11-kDa FKBP12 - rapamycin-binding domain within the 289-kDa FKBP12 - rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci USA 1995;92:4947-51
22. Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12 - rapamycin complex interacting with the binding domain of human FRAP. Science 1996;273:239-42
23. Schalm SS, Fingar DC, Sabatini DM, Blenis J. TOS Motif-mediated Raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol 2003;13:797-806
24. Nojima H, et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signalling (TOS) motif. J Biol Chem 2003;278:15461-4
25. Decker T, Hipp S, Ringshausen I, et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003;101:278-85
26. Huang S, et al. p53/p21CIP1 cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res 2001;61:3373-81
27. Lieberthal W, et al. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001;281:F693-706
28. Woltman AM, et al. Rapamycin specifically interferes with GM-CSF signalling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 2003;101:1439-45
29. Kenerson HL, Aicher LD, True LD, Yeung RS. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumours. Cancer Res 2002;62:5645-50
30. Sarbassov DD, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-68
31. Guba M, Von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumour growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35
32. Hudson CC, et al. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004-14
33. Del Bufalo D, et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006;66:5549-54
34. Thomas GV, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12:122-7
35. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2002;2:489-501
36. Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist 2007;12:1007-18
37. Humar R, Kiefer FN, Berns H, et al. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signalling. FASEB J 2002;16:771-80
38. Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001;8:249-58
39. Dudkin L, Dilling MB, Cheshire PJ, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumour growth inhibition. Clin Cancer Res 2001;7:1758-64
40. Grunwald V, Degraffenried L, Russet D, et al. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002;62:6141-5
41. Geoerger B, Kerr K, Tang CB, et al. Antitumour activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumour/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001;61:1527-32
42. Degraffenried LA, Fulcher L, Friedrichs WE, et al. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the P13 kinase/Akt pathway. Ann Oncol 2004; 15:1510-6
43. Hidalgo M, Buckner JC, Erlichman C, et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 2006;19:5755-63
44. Wu L, Birle DC, Tannock IF. Effects of the mTOR inhibitor CCI-779 used alone or during chemotherapy on human prostate cancer xenografts. Proc Am Assoc Cancer Res 2004;45:3849 [abstract]
45. Gibbons JJ, Discafani C, Peterson R. The effect of CCI-779, a novel macrolide antitumour agent, on the growth of human tumour cells in vitro and in nude mouse xenograft in vivo. Proc Am Assoc Cancer Res 2000;40:301
46. Nashan B. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit 2002;24:53-8
47. Boulay A, Rudloff J, Ye Y, et al. Dual inhibition of mTOR and estrogen receptor signalling in vitro induces cell death in models of beast cancer. Clin Cancer Res 2005;11:5319-28
48. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumour agents: from bench to clinic. Curr Opin Invest Drugs 2002;3:295-304
49. Beuvink I, O'Reilly T, Zumstein S, et al. Antitumour activity of RAD001, an orally-active rapamycin derivative. Proc Am Assoc Cancer Res 2001;42:366
50. Schuler W, Sedrani R, Cottens S, et al. RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997;64:36-42
51. Majewski M, Korecka M, Joergensen J, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from post-transplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003;75:1710-7
52. Mabuchi S, Altomare DA, Cheung M, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007;13:4261-70
53. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumour cells to DNA-damage induced apoptosis through inhibition of p21 translation. Cell 2005;120:747-59
54. O'Reilly T, Vaxelaire J, Muller M, et al. In vivo activity of RAD001, an o rally active rapamycin derivative, in experimental tumour models. Proc Am Assoc Cancer Res 2002;43:71
55. Pollock R, Keats JA, Tang H, et al. Cell shrinkage, cell cycle arrest and antiangiogenesis underlie the antitumour activity of the mTOR inhibitor AP23573 [abstract B160]. Presented at the 15th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 11-15 October 2003
56. Metcalf CA III, Bohacek R, Rozamus LW, et al. Structure-based design of AP23573, a phosphorous-containing analog of rapamycin for antitumour therapy. Proc Am Assoc Cancer Res 2004;45:2476
57. Clackson T, Metcalf CA, Rivera VM, et al. Broad antitumour activity of ap23573, an mTOR inhibitor in clinical development. Proc Am Soc Clin Oncol 2003;22:882
58. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;16:2336-47
59. Peralba JM, Degraffenried L, Friedrichs W, et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 2003;9:2887-92
60. Ching SM, Kuhn J, Wen P, et al. Phase I/Pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs 2004;22:427-35
61. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23:5314-22
62. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-18
63. Pandya KJ, Levy DE, Hidalgo M, et al. A randomized, phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction chemotherapy: a preliminary report. Proc Am Soc Clin Oncol 2005;24:2005
64. Oza A, Elit L, Biagi J, et al. A phase II study of Temsirolimus (CCI-779) in patients with metastatic and/or recurrent endometrial cancer. Clin Cancer Res 2005;11:9099S
65. Oza A, Elit L, Provencher J, et al. A phase II study of temsirolimus(CCI 779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b [abstract 5516]. Proc Am Soc Clin Oncol 2008;26
66. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005;23:5347-56
67. Margolin K, Longmate J, Baratta T, et al. CCI-779 in metastatic melanoma: a Phase II trial of the California Cancer Consortium. Cancer 2005;104:1045-8
68. Chang SM, Wen P, Cloughesy T, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005;23:357-61
69. Alanis E, Buckner JC, Maurer MJ, et al. Phase II trial of Temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005;23:5294-304
70. Muise-Helmericks RC, Grimes HL, Bellacosa A, et al. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/ Akt-dependent pathway. J Biol Chem 1998;273:29864-72
71. Takuwa N, Fukui Y, Takuwa Y. Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70(S6K)-independent signalling in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol 1999;19:1346-58
72. Smith SM, et al. Activity of single agent temsirolimus (CCI779) in non-mantle cell non-Hodgkin lymphoma subtypes [abstract 8514]. Proc Am Soc Clin Oncol 2008
73. Wang SI, Puc J, Li J, et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997;57:4183-6
74. Hurrt MR, Moossy J, Donovan-Peluso M, et al. Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J Neuropathol Exp Neurol 1992;51:84-90
75. Seeliger H, Guba M, Kleespies A, et al. Role of mTOR in solid tumour systems: a therapeutical target against primary tumour growth, metastases, and angiogenesis. Cancer Met Rev 2007;26:611-21
76. Hudes G, Carducci M, Tomczak P. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81
77. Hess G, Romaguera JE, Verhoef G, et al. Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator's choice therapy [abstract 8513]. J Clin Oncol 2008;26
78. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharm 2004;43:83-95
79. Pascual J, Boletis IN, Campistol JM. Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions. Transplant Rev 2006;20:1-18
80. Heisen HJ, Tuzcu M, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant patients. N Engl J Med 2003;349:847-58
81. O'Donnell A, Faivre S, Burris HA, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumours. J Clin Oncol 2008;26:1588-95
82. Papadimitrakopoulou V, Soria JC, Douillard JY, et al. A phase II study of RAD001 monotherapy in patients with advanced non small cell lung cancer failing prior platinum-based chemotherapy or prior chemotherapy and EGFR inhibitors. Proc Am Soc Clin Oncol 2007;25:7589
83. Amato RJ, Misellati A, Khanmet al. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). Proc Am Soc Clin Oncol 2006;24:4530
84. Slomovitz BM, et al. A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus) in patients with recurrent endometrial carcinoma (EC). Proc Am Soc Clin Oncol 2008;26:5502
85. Ellard S, Gelmon K, Chia S, et al. A randomized phase II study of two different schedules of RAD001C in patients with recurrent/metastatic breast cancer [abstract 509]. ASCO; 2007
86. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 2008;372:449-56
87. Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008;26:361-7
88. Desai AA, Mita M, Fetterly GJ, et al. Development of a pharmacokinetic (PK) model and assessment of patient (patient) covariate effects on dose-dependent PK following different dosing schedules in two phase I trials of AP23573 (AP23573), a mTOR inhibitor. Proc Am Soc Clin Oncol 2005;23:3043
89. Mita MM, Britten CD, Poplin E, et al. Deforolimus trial 106 - a phase I trial evaluating 7 regimens of oral deforolimus (AP23573, MK-8669). J Clin Oncol 2008;26:3509
90. Chawla SP, Tolcher AW, Staddon AP, et al. Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patient (pts) with advanced soft tissue or bone sarcomas. Proc Am Soc Clin Oncol 2006;24:9505
91. Rizzieri DA, Feldman E, Dipersio JF, et al. A phase II clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008;14:2756-62
92. Colombo N, McMeekin S, Schwartz P, et al. A phase II trial of the mTOR inhibitor AP23573 as single agent in advanced endometrial cancer. Proc Am Soc Clin Oncol 2007;25:5516
93. Shah OJ, Hunter T. Critical role of T-loop and H-motif phosphorylation in the regulation of S6 kinase 1 by the tuberous sclerosis complex. J Biol Chem 2004;279:20816-23
94. Oza A, Elit L, Biagi J, et al. Molecular correlates associated with a phase II study of temsirolimus in recurrent endometrial cancer-NCIC IND 160 [abstract 3003]. Proc Am Soc Clin Oncol 2006
95. Kurmasheva RT, Huang S, Houghton PJ. Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer 2006;95:955-60
96. Li S, Takasu T, Perlman DM, et al. Translation factor cIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release. J Biol Chem 2003;278:3015-22
97. Boulay A, et al. Antitumour efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonghed inactivation of ribosomal protein S6 kinase1 in peripheral blood mononuclear cells. Cancer Res 2004;64:252-61
98. Reardon D, et al. A phase I trial of AP23573, a novel mTOR inhibitor, in patients with recurrent malignant glioma. Proc 17th Symp Mol Targets Cancer Ther 2005;105:AC195
99. Lane HA, Tanaka C, Kovarik T, et al. Preclinical and clinical pharmacokinetic/pharmacodynamic (PK/PD) modelling to help define an optimal biological dose for the oral mTOR inhibitor RAD001, in oncology. Proc Am Soc Clin Oncol 2003;22:237
100. Van Kesteren CH, Mathot RA, Beijnen JH, et al. Pharmacokinetic-pharmacodynamic guided trial design in oncology. Invest New Drugs 2003;21:225-41
101. Tanaka C, O'Reilly T, Kovarik JM, et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008;26:1596-602
102. Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumour pharmacodynamic study in patients with advanced solid tumours. J Clin Oncol 2008;26:1603-10
103. Abraham RT, Gibbons JJ. The mammalian target of Rapamycin signalling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007;13:3109-114
104. Patnaik A, Ricart A, Cooper J, et al. A phase I, pharmacokinetic and pharmacodynamic study of sorafenib, a multitargeted kinase inhibitor in combination with temsirolimus, an mTOR inhibitor in patients with advanced solid tumours [abstract 3512]. Proc Am Soc Clin Oncol (ASCO) 2007
105. Cresta S, Tosi D, Sessa C, et al. Phase Ib study defining the optimal dosing combinations of the mTOR inhibitor APZ23573 and paclitaxel (PTX) [abstract 3509]. Proc Am Soc Clin Oncol (ASCO) 2007